The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.
Current evidence inadequate for assessing balance of benefits, harms of interventions among youth.
The FDA has accepted for review the New Drug Application for dasiglucagon HypoPal® Rescue Pen (Zealand Pharma) for the treatment of severe hypoglycemia.
The use of immune globulin therapy appears to benefit children who experience acute heart failure caused by coronavirus disease 2019 (COVID-19)-related multisystem inflammatory syndrome, according to the findings of a case series recently published in Circulation.
The FDA has accepted for Priority Review the New Drug Application (NDA) for lonafarnib (Zokinvy™; Eiger BioPharmaceuticals) for the treatment of progeria and progeroid laminopathies, rare, genetic conditions of accelerated aging in children.
Prenatal and early life exposure to household air pollution may affect the development of lung function and lead to an increase in airway resistance in children.
AR19 is an investigational immediate-release, amphetamine formulated to prevent the manipulation of the pellets in the capsules for nonmedical use.
Children diagnosed after start of SARS-CoV-2 were older, had higher rate of cardiac involvement.
Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).
The FDA has granted accelerated approval to Retevmo™ (selpercatinib; Lilly).
